Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Model-informed dose selection for Xentuzumab, a dual insulin-like growth factor-I/II -neutralizing antibody.

Parra-Guillen ZP, Schmid U, Janda A, Freiwald M, Troconiz IF.

Clin Pharmacol Ther. 2019 Sep 28. doi: 10.1002/cpt.1648. [Epub ahead of print]

PMID:
31562819
2.

Immune network for viral hepatitis B: Topological representation.

Asín-Prieto E, Parra-Guillen ZP, Mantilla JDG, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF.

Eur J Pharm Sci. 2019 Aug 1;136:104939. doi: 10.1016/j.ejps.2019.05.017. Epub 2019 Jun 10.

PMID:
31195071
3.

The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing.

Melin J, Hartung N, Parra-Guillen ZP, Whitaker MJ, Ross RJ, Kloft C.

Clin Endocrinol (Oxf). 2019 Jul;91(1):33-40. doi: 10.1111/cen.13969. Epub 2019 Apr 9.

PMID:
30868607
4.

Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.

Vera-Yunca D, Serrano-Mendioroz I, Sampedro A, Jericó D, Trocóniz IF, Fontanellas A, Parra-Guillén ZP.

Mol Genet Metab. 2018 Dec 21. pii: S1096-7192(18)30574-2. doi: 10.1016/j.ymgme.2018.12.009. [Epub ahead of print]

PMID:
30639045
5.

Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.

Parra-Guillen ZP, Mangas-Sanjuan V, Garcia-Cremades M, Troconiz IF, Mo G, Pitou C, Iversen PW, Wallin JE.

J Pharmacol Exp Ther. 2018 Jul;366(1):96-104. doi: 10.1124/jpet.118.248286. Epub 2018 Apr 24.

PMID:
29691287
6.

The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing.

Ruiz-Cerdá L, Asín-Prieto E, Parra-Guillen ZP, Trocóniz IF.

Clin Cancer Res. 2018 Jul 15;24(14):3236-3238. doi: 10.1158/1078-0432.CCR-18-0580. Epub 2018 Mar 26.

7.

Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults.

Melin J, Parra-Guillen ZP, Hartung N, Huisinga W, Ross RJ, Whitaker MJ, Kloft C.

Clin Pharmacokinet. 2018 Apr;57(4):515-527. doi: 10.1007/s40262-017-0575-8.

PMID:
28762136
8.

Model Description Language (MDL): A Standard for Modeling and Simulation.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N; DDMoRe consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12. No abstract available.

9.

Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.

Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen ZP.

J Pharmacol Exp Ther. 2017 Aug;362(2):347-358. doi: 10.1124/jpet.117.240309. Epub 2017 Jun 9.

PMID:
28600397
10.

Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.

Klopp-Schulze L, Joerger M, Wicha SG, Ter Heine R, Csajka C, Parra-Guillen ZP, Kloft C.

Clin Pharmacokinet. 2018 Feb;57(2):229-242. doi: 10.1007/s40262-017-0555-z.

PMID:
28540639
11.

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen S, Krähenbühl S, Kloft C, Joerger M.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19.

12.

Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
.

Klopp-Schulze L, Joerger M, Wicha SG, Parra-Guillen ZP, Kloft C.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):690-691. doi: 10.5414/CPXCES15EA05. No abstract available.

PMID:
27641215
13.

Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer - Proof of concept towards a systems pharmacology approach.

Saafan H, Foerster S, Parra-Guillen ZP, Hammer E, Michaelis M, Cinatl J Jr, Völker U, Fröhlich H, Kloft C, Ritter CA.

Eur J Pharm Sci. 2016 Oct 30;94:20-32. doi: 10.1016/j.ejps.2016.04.025. Epub 2016 Apr 23.

PMID:
27112992
14.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.

Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):316-9. doi: 10.1002/psp4.57. Epub 2015 Jun 15.

15.

Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.

Edlund H, Melin J, Parra-Guillen ZP, Kloft C.

Clin Pharmacokinet. 2015 Jan;54(1):35-80. doi: 10.1007/s40262-014-0208-4. Review.

PMID:
25516414
16.

Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake.

Parra-Guillen ZP, Cendrós Carreras JM, Peraire C, Obach R, Prunynosa J, Chetaille E, Trocóniz IF.

Pharm Res. 2015 Apr;32(4):1493-504. doi: 10.1007/s11095-014-1555-4. Epub 2014 Oct 30.

PMID:
25355461
17.

Modeling tumor response after combined administration of different immune-stimulatory agents.

Parra-Guillen ZP, Berraondo P, Ribba B, Trocóniz IF.

J Pharmacol Exp Ther. 2013 Sep;346(3):432-42. doi: 10.1124/jpet.113.206961. Epub 2013 Jul 11.

PMID:
23845890
18.

Mathematical model approach to describe tumour response in mice after vaccine administration and its applicability to immune-stimulatory cytokine-based strategies.

Parra-Guillen ZP, Berraondo P, Grenier E, Ribba B, Troconiz IF.

AAPS J. 2013 Jul;15(3):797-807. doi: 10.1208/s12248-013-9483-5. Epub 2013 Apr 19.

19.

Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.

Parra-Guillen ZP, Janda A, Alzuguren P, Berraondo P, Hernandez-Alcoceba R, Troconiz IF.

AAPS J. 2013 Jan;15(1):183-94. doi: 10.1208/s12248-012-9423-9. Epub 2012 Nov 8.

20.

Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I.

Parra-Guillen ZP, Fioravanti J, Medina-Echeverz J, Gomar C, Ardaiz N, Troconiz IF, Berraondo P.

PLoS One. 2012;7(7):e42100. doi: 10.1371/journal.pone.0042100. Epub 2012 Jul 27.

21.

The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism.

Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillén ZP, Prieto J, Berraondo P.

J Immunol. 2012 Apr 15;188(8):3988-92. doi: 10.4049/jimmunol.1101598. Epub 2012 Mar 14.

22.

Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Parra-Guillén ZP, González-Aseguinolaza G, Berraondo P, Trocóniz IF.

Pharm Res. 2010 Aug;27(8):1487-97. doi: 10.1007/s11095-010-0136-4. Epub 2010 Apr 13. Review.

PMID:
20387096

Supplemental Content

Loading ...
Support Center